Novel report of expression and function of CD97 in malignant gliomas: Correlation with Wilms tumor 1 expression and glioma cell invasiveness - Laboratory investigation

Journal of Neurosurgery

Volumn 116, Issue 4, 2012, Pages 843-853

  Chidambaram, Archana ^a   Fillmore, Helen L ^a,b   Van Meter, Timothy E ^a   Dumur, Catherine I ^a   Broaddus, William C ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OLD DOMINION UNIVERSITY   (United States)

Author keywords

Glioblastoma; Invasiveness; Oncology; Target genes; Wilms tumor 1

Indexed keywords

CD97 ANTIGEN; CYTOKERATIN 18; LEUCINE ZIPPER PROTEIN; PLATELET DERIVED GROWTH FACTOR D; SMALL INTERFERING RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRANSCRIPTION FACTOR SOX11; WT1 PROTEIN;

ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ARTICLE; CANCER INVASION; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE SILENCING; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; NEPHROBLASTOMA; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE;

ALLELES; ANTIGENS, CD; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; EXONS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC ASSOCIATION STUDIES; GLIOMA; HUMANS; NEOPLASM INVASIVENESS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TUMOR STEM CELL ASSAY; WT1 PROTEINS;

EID: 84859364857     PISSN: 00223085     EISSN: 19330693     Source Type: Journal    
DOI: 10.3171/2011.11.JNS111455     Document Type: Article

References (49)

1. Aust G, Eichler W, Laue S, Lehmann I, Heldin NE, Lotz O, et al: CD97: a dedifferentiation marker in human thyroid carcinomas. Cancer Res 57:1798-1806, 1997 (Pubitemid 27199676)
2. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, et al: The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15:5323-5337, 2009
3. Chen MY, Clark AJ, Chan DC, Ware JL, Holt SE, Chidambaram A, et al: Wilms' tumor 1 silencing decreases the viability and chemoresistance of glioblastoma cells in vitro: a potential role for IGF-1R de-repression. J Neurooncol 103:87-102, 2011
4. Clark AJ, Chan DC, Chen MY, Fillmore HL, Dos Santos WG, Van Meter TE, et al: Down-regulation of Wilms' tumor 1 expression in glioblastoma cells increases radiosensitivity independently of p53. J Neurooncol 83:163-172, 2007 (Pubitemid 46784989)
5. Clark AJ, Dos Santos WG, McCready J, Chen MY, Van Meter TE, Ware JL, et al: Wilms tumor 1 expression in malignant gliomas and correlation of +KTS isoforms with p53 status. J Neurosurg 107:586-592, 2007 (Pubitemid 47451043)
6. Clark AJ, Ware JL, Chen MY, Graf MR, Van Meter TE, Dos Santos WG, et al: Effect of WT1 gene silencing on the tumorigenicity of human glioblastoma multiforme cells. Laboratory investigation. J Neurosurg 112:18-25, 2010
7. Dudnakova T, Spraggon L, Slight J, Hastie N: Actin: a novel interaction partner of WT1 influencing its cell dynamic properties. Oncogene 29:1085-1092, 2010
8. Dumur CI, Nasim S, Best AM, Archer KJ, Ladd AC, Mas VR, et al: Evaluation of quality-control criteria for microarray gene expression analysis. Clin Chem 50:1994-2002, 2004 (Pubitemid 39425835)
9. Dumur CI, Sana S, Ladd AC, Ferreira-Gonzalez A, Wilkinson DS, Powers CN, et al: Assessing the impact of tissue devitalization time on genome-wide gene expression analysis in ovarian tumor samples. Diagn Mol Pathol 17:200-206, 2008
10. Garrido-Ruiz MC, Rodriguez-Pinilla SM, Pérez-Gómez B, Rodriguez-Peralto JL: WT 1 expression in nevi and melanomas: a marker of melanocytic invasion into the dermis. J Cutan Pathol 37:542-548, 2010
11. Gerald WL, Haber DA: The EWS-WT1 gene fusion in desmoplastic small round cell tumor. Semin Cancer Biol 15:197-205, 2005
12. Giannini C, Sarkaria JN, Saito A, Uhm JH, Galanis E, Carlson BL, et al: Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro Oncol 7:164-176, 2005 (Pubitemid 40590516)
13. Gray JX, Haino M, Roth MJ, Maguire JE, Jensen PN, Yarme A, et al: CD97 is a processed, seven-transmembrane, heterodimeric receptor associated with inflammation. J Immunol 157:5438-5447, 1996 (Pubitemid 126448963)
14. Han SL, Xu C, Wu XL, Li JL, Liu Z, Zeng QQ: The impact of expressions of CD97 and its ligand CD55 at the invasion front on prognosis of rectal adenocarcinoma. Int J Colorectal Dis 25:695-702, 2010
15. Hohenstein P, Hastie ND: The many facets of the Wilms'tumour gene, WT1. Hum Mol Genet 15 Spec No 2:R196-R201, 2006 (Pubitemid 44446794)
16. Huff V: Wilms' tumours: about tumour suppressor genes, an oncogene and a chameleon gene. Nat Rev Cancer 11:111-121, 2011
17. Izumoto S, Tsuboi A, Oka Y, Suzuki T, Hashiba T, Kagawa N, et al: Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J Neurosurg 108:963-971, 2008 (Pubitemid 351656845)
18. Jomgeow T, Oji Y, Tsuji N, Ikeda Y, Ito K, Tsuda A, et al: Wilms' tumor gene WT1 17AA(-)/KTS(-) isoform induces morphological changes and promotes cell migration and invasion in vitro. Cancer Sci 97:259-270, 2006
19. Kreidberg JA, Sariola H, Loring JM, Maeda M, Pelletier J, Housman D, et al: WT-1 is required for early kidney development. Cell 74:679-691, 1993 (Pubitemid 23259748)
20. Kwakkenbos MJ, Kop EN, Stacey M, Matmati M, Gordon S, Lin HH, et al: The EGF-TM7 family: a postgenomic view. Immunogenetics 55:655-666, 2004 (Pubitemid 38221665)
21. Liu Y, Chen L, Peng S, Chen Z, Gimm O, Finke R, et al: The expression of CD97EGF and its ligand CD55 on marginal epithelium is related to higher stage and depth of tumor invasion of gastric carcinomas. Oncol Rep 14:1413-1420, 2005
22. Loeb DM, Evron E, Patel CB, Sharma PM, Niranjan B, Buluwela L, et al: Wilms' tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumor-specific promoter methylation. Cancer Res 61:921-925, 2001 (Pubitemid 32174404)
23. Mayo MW, Wang CY, Drouin SS, Madrid LV, Marshall AF, Reed JC, et al: WT1 modulates apoptosis by transcriptionally upregulating the bcl-2 proto-oncogene. EMBO J 18:3990-4003, 1999 (Pubitemid 29335852)
24. Miyagi T, Ahuja H, Kubota T, Kubonishi I, Koeffler HP, Miyoshi I: Expression of the candidate Wilm's tumor gene, WT1, in human leukemia cells. Leukemia 7:970-977, 1993 (Pubitemid 23230975)
25. Oji Y, Inohara H, Nakazawa M, Nakano Y, Akahani S, Nakatsuka S, et al: Overexpression of the Wilms' tumor gene WT1 in head and neck squamous cell carcinoma. Cancer Sci 94:523-529, 2003 (Pubitemid 36849717)
26. Oji Y, Miyoshi S, Maeda H, Hayashi S, Tamaki H, Nakatsuka S, et al: Overexpression of the Wilms' tumor gene WT1 in de novo lung cancers. Int J Cancer 100:297-303, 2002 (Pubitemid 34728987)
27. Oji Y, Miyoshi Y, Koga S, Nakano Y, Ando A, Nakatsuka S, et al: Overexpression of the Wilms' tumor gene WT1 in primary thyroid cancer. Cancer Sci 94:606-611, 2003 (Pubitemid 36975015)
28. Oji Y, Nakamori S, Fujikawa M, Nakatsuka S, Yokota A, Tatsumi N, et al: Overexpression of the Wilms' tumor gene WT1 in pancreatic ductal adenocarcinoma. Cancer Sci 95:583-587, 2004 (Pubitemid 39089639)
29. Oji Y, Ogawa H, Tamaki H, Oka Y, Tsuboi A, Kim EH, et al: Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn J Cancer Res 90:194-204, 1999 (Pubitemid 29112320)
30. Oji Y, Yamamoto H, Nomura M, Nakano Y, Ikeba A, Nakatsuka S, et al: Overexpression of the Wilms' tumor gene WT1 in colorectal adenocarcinoma. Cancer Sci 94:712-717, 2003 (Pubitemid 37160929)
31. Oji Y, Yano M, Nakano Y, Abeno S, Nakatsuka S, Ikeba A, et al: Overexpression of the Wilms' tumor gene WT1 in esophageal cancer. Anticancer Res 24:3103-3108, 2004 (Pubitemid 39390958)
32. Oka Y, Sugiyama H: WT1 peptide vaccine, one of the most promising cancer vaccines: its present status and the future prospects. Immunotherapy 2:591-594, 2010
33. Oka Y, Tsuboi A, Fujiki F, Li Z, Nakajima H, Hosen N, et al: WT1 peptide vaccine as a paradigm for "cancer antigen-derived peptide"-based immunotherapy for malignancies: successful induction of anti-cancer effect by vaccination with a single kind of WT1 peptide. Anticancer Agents Med Chem 9:787-797, 2009
34. Perugorria MJ, Castillo J, Latasa MU, Goñi S, Segura V, Sangro B, et al: Wilms' tumor 1 gene expression in hepatocellular carcinoma promotes cell dedifferentiation and resistance to chemotherapy. Cancer Res 69:1358-1367, 2009
35. Scharnhorst V, van der Eb AJ, Jochemsen AG: WT1 proteins: functions in growth and differentiation. Gene 273:141-161, 2001 (Pubitemid 32786908)
36. Scholz H, Wagner KD, Wagner N: Role of the Wilms' tumour transcription factor, Wt1, in blood vessel formation. Pflugers Arch 458:315-323, 2009
37. Sugiyama H: WT1 (Wilms' tumor gene 1): biology and cancer immunotherapy. Jpn J Clin Oncol 40:377-387, 2010
38. Tamaki H, Ogawa H, Ohyashiki K, Ohyashiki JH, Iwama H, Inoue K, et al: The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes. Leukemia 13:393-399, 1999 (Pubitemid 29108078)
39. Ueda T, Oji Y, Naka N, Nakano Y, Takahashi E, Koga S, et al: Overexpression of the Wilms' tumor gene WT1 in human bone and soft-tissue sarcomas. Cancer Sci 94:271-276, 2003 (Pubitemid 36575894)
40. Van Meter TE, Dumur CI, Hafez N, Garrett C, Fillmore HL, Broaddus WC: Microarray analysis of MRI-defined tissue samples in glioblastoma reveals differences in regional expression of therapeutic targets. Diagn Mol Pathol 15:195-205, 2006 (Pubitemid 44813658)
41. Veninga H, Becker S, Hoek RM, Wobus M, Wandel E, van der Kaa J, et al: Analysis of CD97 expression and manipulation: antibody treatment but not gene targeting curtails granulocyte migration. J Immunol 181:6574-6583, 2008
42. Wagner N, Michiels JF, Schedl A, Wagner KD: The Wilms'tumour suppressor WT1 is involved in endothelial cell proliferation and migration: expression in tumour vessels in vivo. Oncogene 27:3662-3672, 2008 (Pubitemid 351912975)
43. Wang T, Ward Y, Tian L, Lake R, Guedez L, Stetler-Stevenson WG, et al: CD97, an adhesion receptor on inflammatory cells, stimulates angiogenesis through binding integrin counterreceptors on endothelial cells. Blood 105:2836-2844, 2005 (Pubitemid 40446277)
44. Wang Z, Ahmad A, Li Y, Kong D, Azmi AS, Banerjee S, et al: Emerging roles of PDGF-D signaling pathway in tumor development and progression. Biochim Biophys Acta 1806:122-130, 2010
45. Wang ZY, Qiu QQ, Enger KT, Deuel TF: A second transcriptionally active DNA-binding site for the Wilms tumor gene product, WT1. Proc Natl Acad Sci U S A 90:8896-8900, 1993 (Pubitemid 23306417)
46. Yang L, Han Y, Suarez Saiz F, Minden MD: A tumor suppressor and oncogene: the WT1 story. Leukemia 21:868-876, 2007 (Pubitemid 46672061)
47. Yona S, Lin HH, Siu WO, Gordon S, Stacey M: Adhesion- GPCRs: emerging roles for novel receptors. Trends Biochem Sci 33:491-500, 2008
48. Zhang L, Wang L, Ravindranathan A, Miles MF: A new algorithm for analysis of oligonucleotide arrays: application to expression profiling in mouse brain regions. J Mol Biol 317:225-235, 2002 (Pubitemid 34722190)
49. Zhao Y, Xiao A, diPierro CG, Carpenter JE, Abdel-Fattah R, Redpath GT, et al: An extensive invasive intracranial human glioblastoma xenograft model: role of high level matrix metalloproteinase 9. Am J Pathol 176:3032-3049, 2010